[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355700-105":59,"doc-detail-355700-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","human-epidermal-growth-factor-receptor-2-expression-in-prostatic-carcinomas-a-systematic-review-and-meta-analysis-of-a-potential-therapeutic-target","Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas - A Systematic Review and Meta-Analysis of a Potential Therapeutic Target","","This systematic review and meta-analysis evaluates the prevalence of HER (over)expression in prostate cancer and seeks patient and disease subgroups with enriched HER2 overexpression. Searches across five databases extracted HER2 scores and clinicopathological cross-tabulations for pooled prevalence and odds ratio analyses. Sixteen studies (1258 cases) were synthesized; HER2 score 3 showed low prevalence, while HER2 non-negative expression was common, with subgroup associations linked to higher Gleason score and advanced stage.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/human-epidermal-growth-factor-receptor-2-expression-in-prostatic-carcinomas-a-systematic-review-and-meta-analysis-of-a-potential-therapeutic-target/355700/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/human-epidermal-growth-factor-receptor-2-expression-in-prostatic-carcinomas-a-systematic-review-and-meta-analysis-of-a-potential-therapeutic-target/355700.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the review?","Question",{"text":112,"@type":113},"To determine how often HER2 (HER over)expression occurs in prostate cancer and to identify subgroups with higher likelihood of HER2 overexpression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were HER2 expression and related outcomes analyzed?",{"text":117,"@type":113},"HER2 scores and clinicopathological parameters were extracted and pooled for prevalence and odds ratio analyses, with study quality and heterogeneity assessed.",{"name":119,"@type":110,"acceptedAnswer":120},"Which clinical features were associated with HER2 overexpression?",{"text":121,"@type":113},"HER2 overexpression correlated with higher Gleason score and more advanced disease stage, while age and PSA level showed no significant difference.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355700,1790452528,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","The Prostate   \nORIGINAL ARTICLE   \nHuman Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target  \nJacky T. F. Luk1 | Alex H. Lin1 | Esther K. C. Cheung1 | Renald Meçani2,3 | Taulant Muka2  | Jana Nano4 | Joanna K. M. Ng1 | Matthew K. L. Chiu5 | Bryan C. W. Li6 | Rong Na7 | Joshua J. X. Li1   \n1Department of Pathology, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR | 2Epistudia, Bern, Switzerland | 3Department of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria | 4Department of Radiation Oncology, TUM School of Medicine and Health, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany | 5Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR | 6Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR | 7Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR  \nCorrespondence: Joshua J. X. Li (joshuajl@hku.hk)  \nReceived: 20 February 2026 | Revised: 23 March 2026 | Accepted: 12 April 2026  \nKeywords: HER2 | immunohistochemistry | meta‐analysis | prostate cancer | targeted therapy  \nABSTRACT  \nIntroduction: The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta‐analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.  \nMethods: Literature searches of five databases were performed. HER2 scores with cross‐tabulation of clinicopathological parameters were extracted for pooled prevalence and odds ratio analyses. Study quality, heterogeneity, and publication bias were assessed by the CASP checklist, I2 index, and LFK index.  \nResults: In total, 16 studies were included with 1258 cases. There were 669 (53 . 18%), 269 (21 . 38%), 250 (19 .87%), and 70 (5 . 56%) of HER2 Scores 0/1/2/3, respectively. Pooled analysis indicated a prevalence of 4.9%(95% CI 3.0%–7.2%) for HER2 Score 3 and 42.0%(95% CI 29.0%–55.6%) for HER2 non‐negative (Scores 1–3). Subgroup analysis comparing HER2 negative (0, 1) and HER2 overexpression (3) indicated higher Gleason score (OR = 0.061, 95% CI: 0.010–0.359, p \u003C 0.001), higher disease stage (OR = 0.063, 95% CI: 0.016–0.252, p \u003C 0.001) and biopsies from metastatic site (OR: > 100, 95% C.I.: > 100–> 100, p \u003C 0.001) favoring HER overexpression, without significant differences for patient age or prostate‐specific antigen (PSA) level. I2 was 91.63% with meta‐regression analysis showing study quality as a source of heterogeneity (p = 0.043) . LFK index was 1.93 (moderate publication bias risk, p = 0.054) .  \nConclusions: HER2 overexpression is rare in prostatic carcinomas but nearly half show HER2 expression of Score 1 or above. Cases with higher Gleason score and advanced disease stage are more likely to overexpress HER2 .  \n1 | Introduction  \nThe human epidermal growth factor receptor 2 (HER2) is extensively involved in the tumorigenesis of human cancers with promising HER2 related therapeutic agents successfully developed targeting HER expressing cancers [1, 2] . In the case of  \nprostatic carcinoma, the interest on HER2 expression, testing, and treatment has been small as early trials did not demonstrate efficacy for the HER2 inhibitor trastuzumab [1]. The interest in HER2 testing for prostatic carcinoma has been renewed by the availability of antibody–drug conjugates, specifically trastuzumab  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . The Prostate published by Wiley Periodicals LLC.  \nThe Prostate, 2026; 86:1061–1068 1061  \n[http","cbCaicRvumaSy1LF","https://ap.wps.com/l/cbCaicRvumaSy1LF","pdf",1397306,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Methods\n## Study Design\n## Literature Search\n## Study Selection","[{\"question\":\"What is the main objective of the review?\",\"answer\":\"To determine how often HER2 (HER over)expression occurs in prostate cancer and to identify subgroups with higher likelihood of HER2 overexpression.\"},{\"question\":\"How were HER2 expression and related outcomes analyzed?\",\"answer\":\"HER2 scores and clinicopathological parameters were extracted and pooled for prevalence and odds ratio analyses, with study quality and heterogeneity assessed.\"},{\"question\":\"Which clinical features were associated with HER2 overexpression?\",\"answer\":\"HER2 overexpression correlated with higher Gleason score and more advanced disease stage, while age and PSA level showed no significant difference.\"}]","Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas - A Systematic Review and Meta-Analysis of a Potential Therapeutic Target | PDF",1790120538,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11302c7ddd656fa3f0e765f096eb4a49.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26b29e93e701e85f0e6db3f91f80a9d8.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/643cbdcd433d95db95b3353e556e6abf.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c4591151e8e089c896a4cd971fb70ac.webp",980,1287]